Navigation Links
Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission

The pharmaceutical company Starpharma saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent transmission of HIV. // The company even signed a $20 million (US) contract with the US National Institute of Allergy and Infectious Diseases, an integral part of the National Institute of Health.

'There are currently no approved products for the prevention of HIV infection. The FDA recognizes the potential of Vivagel to address this unmet medical need. Vivagel's new drug application will now receive priority review, which has a shorter assessment time. The early review is expected to shorten FDA's approval time significantly', said John Raff, Chief executive of Starpharma.

It is further hoped that the FDA’s initiative to accelerate the approval process would contribute to the development of the company, in the opinion of Jackie Fairley, Chief operating officer, Starpharma.

It was anticipated that the approval and commercial use of the drug would take about 13 months. With this green signal from the FDA, it could be materialized in less than 6 or 7 months according to official reports.

The product is primarily targeted at women, and would help them prevent contracting sexually transmitted diseases such as genital herpes, HIV and so on. The drug, a vaginal formulation has to be topically applied prior to intercourse and would function as a chemical barrier against various infections.

'Vivagel is not a treatment for HIV. The gel is used topically prior to sexual intercourse to prevent the women from becoming infected with HIV, genital herpes and other sexually transmitted diseases', said Dr Fairley.

AIDS is increasingly becoming a global burden, with nearly 40 million people afflicted with the disease worldwide. The number of genital herpes and AIDS/HIV in Australia is estimated to be 3.4 million and 15, 000 respectively. This is of great importan
'"/>




Page: 1 2

Related medicine news :

1. Kirin Develops a Cure for Bird Flu
2. Hungary Develops New Bird Flu Vaccine
3. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
4. Samsung Develops Device to Measure Body Fat
5. India Develops Test for Diagnosis of Deadly Livestock Disease
6. Mouth Cancer Develops In Two Different Ways
7. John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases
8. Researcher Develops Sensor to Detect E.coli
9. Australian Firm Develops Low Glycaemic Sugar to Prevent Diabetes
10. US Company Develops Better Weight Reduction Pill
11. Rhode Island Biotechnology Company Develops Tularemia Vaccine
Post Your Comments:
(Date:7/25/2008)...benefit ALS Therapy Alliance to be presented at Fe... WOONSOCKET, R.I., July 25 /PRNewswire/ -- CVS/pha... a record-breaking $4.4 million in just 21 days,th... ALS research. This is,the seventh year of the ann...more than $15 million for ALS research. This year,...
(Date:7/25/2008)... New program delivers immediate cost s...hour telephone access to language interpreters] t...ltilingual solutions. , W...reg; http://www.lle-inc.com/index.html [(Languag... of interpretation, translation, and language inst...
(Date:7/25/2008)... This donation will be used to facilit...ervices for children , Ha...ww.ivci.com ), a leading integrator of enterprise... video conferencing, telepresence, audio visual in...unced today that it has donated video conferencing...
(Date:7/24/2008)...N, July 24 /PRNewswire-USNewswire/ -- Speaker Nanc...ning in support of the Tom Lantos,and Henry J. Hyd..., and,Malaria Reauthorization Act of 2008. The bil...ouse this evening by a vote of 303 to 115 and will... "Today the House took an historic vote to pass l...
Breaking Medicine News(10 mins):Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...birth do survive into adolescence, a study conduct...lly it is believed that virtually all children inf.... But doctors working in sub-Saharan Africa have b...dmitted in HIV clinics. Researchers from the Well...
...bs with the NHS in the last quarter of 2006.The to...as per official statistics//. The job-cuts may be ...take a toll on patient care. Most of the redunda... category. Nevertheless, for those who have lost t...
...es cause a bizarre but dangerous side effect -- sl...n (FDA) has warned. Those who take the pills co...y may have no memory of having taken a tablet at a...g phone calls or fixing and eating food even while...
...which was in use even in ancient civilizations, ...//hospital settings. Scientists of the NHS who a...ich are taking over many hospitals across U.K, are...erial properties of this metal to use. Selly Oaks...
Other Medicine News:Health News:Trial Run of Copper to Combat MRSA 2
(Date:7/23/2008)...erapy to Treat the Disease -, WAYNE, N.J. and EME...,Bayer HealthCare Pharmaceuticals and Onyx Pharmac... The New England Journal of Medicine published,res...(R) (sorafenib),tablets decreased the absolute ris...able hepatocellular carcinoma (HCC), or liver canc...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/22/2008)...center 293-patient European, trial -, http://ww...YT, MONTREAL, July 22 / Cr...cryotherapy products to treat cardiac,arrhythmias,... from three,European study centers using the Compa... earlier today in the Journal of the American Coll...
(Date:7/22/2008)...ma Exhibits Excellent Drug-Like ...itiation of Phase II Clinical Trials -, RESEARCH ...x BioPharma,Inc., a clinical stage company develo... diseases of the central nervous system, today ann...TM) into Phase II trials for the,treatment of depr...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Novo Nordisk Settles With Pfizer On Patent Infringement Suit 8008 1CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 1CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 2CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 3CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 4CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 5CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 6CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End of Phase II Meeting with FDA 8003 7Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 1Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 2Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 3Kidney Patients Health Is Jeopardized by Proposed Medicare Changes 7998 4FDLI PEN co sponsor major conference on nanotechnology 1536 1FDLI PEN co sponsor major conference on nanotechnology 1536 2FDLI PEN co sponsor major conference on nanotechnology 1536 3
...est, Most Comprehensive Survey Provides New Benchm...June 21, 2007 /PRNewswire-USNewswire/ -- The,follo... -- First nationwide study of the prevalence of M... (MRSA), a virulent multi-drug resistant organism,...RSA prevalence study findings significantly exceed...
...TAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- M...ill present Phase 2,data from its Unit Dose Budeso...am at the World Asthma Meeting at the Lutfi Kirdar...key. , The oral and poster presentation entitled, ... formulation of budesonide for,nebulized delivery ...
Other Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2
Craniosorb Absorbable Fixation System (AFS) is uniquely designed to offer simple and reproducible fixation of the cranial flap and allow for complete absorption of the plating system over time.
1.7/2.2 mm Delta System resorbable implant technology merges science and simplicity for a superior craniomaxillofacial surgery product. The system consists of resorbable bone plates and screws fabric
By combining intra-operative ultrasound imaging with preoperative imagery, Medtronic Surgical Navigation Technologies has created a revolutionary product called SonoNav Intra-operative Imaging System
...oglue) is a two-component surgical adhesive compos...araldehyde. The BSA is obtained from cattle exclus...free countries and undergoes processing that reduc...nsed by a controlled delivery system, composed of ...
Medicine Products: